U.S. markets closed
  • S&P 500

    4,246.59
    -8.56 (-0.20%)
     
  • Dow 30

    34,299.33
    -94.42 (-0.27%)
     
  • Nasdaq

    14,072.86
    -101.29 (-0.71%)
     
  • Russell 2000

    2,320.07
    -6.07 (-0.26%)
     
  • Crude Oil

    72.42
    +1.54 (+2.17%)
     
  • Gold

    1,860.50
    -5.40 (-0.29%)
     
  • Silver

    27.78
    -0.26 (-0.92%)
     
  • EUR/USD

    1.2130
    +0.0007 (+0.06%)
     
  • 10-Yr Bond

    1.4990
    -0.0020 (-0.13%)
     
  • GBP/USD

    1.4084
    -0.0024 (-0.17%)
     
  • USD/JPY

    110.0430
    -0.0180 (-0.02%)
     
  • BTC-USD

    40,020.20
    +277.77 (+0.70%)
     
  • CMC Crypto 200

    995.68
    -14.93 (-1.48%)
     
  • FTSE 100

    7,172.48
    +25.80 (+0.36%)
     
  • Nikkei 225

    29,441.30
    +279.50 (+0.96%)
     

Processa Pharmaceuticals to Present at LD Micro Virtual Investor Conference on June 9, 2021, at 1:30pm ET

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

HANOVER, MD, June 07, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, announced today that management will present at:

LD Micro Virtual Investor Conference
Date: June 9, 2021
Time: 1:30 p.m. ET – Track 4
Webcast: https://ldmicrojune2021.mysequire.com

A live audio webcast and archive of the event presentation will be available using the webcast link above. For more information on the LD Micro Invitational XI, or to register for the event, please visit https://ldmicrojune2021.mysequire.com

About Processa Pharmaceuticals, Inc.

The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with unmet or underserved medical conditions who need treatment options that improve survival and/or quality of life. The Company uses these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently. Active clinical pipeline programs include: PCS6422 (metastatic colorectal cancer and breast cancer), PCS499 (ulcerative necrobiosis lipoidica) and PCS12852 (GI motility/gastroparesis). The members of the Processa development team have been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and more than 100 FDA meetings throughout their careers. For more information, visit the company’s website at www.ProcessaPharma.com .

Forward-Looking Statements

This release contains forward-looking statements. The statements in this press release that are not purely historical are forward-looking statements which involve risks and uncertainties. Actual future performance outcomes and results may differ materially from those expressed in forward-looking statements. Please refer to the registration statement relating to the securities being sold in this offering, which identifies important risk factors which could cause actual results to differ from those contained in the forward-looking statements.

For More Information:
Michael Floyd
mfloyd@processapharma.com
301-651-4256

James Carbonara
Hayden IR
(646) 755-7412
james@haydenir.com